NCT07319169

Brief Summary

Recent evidence suggests that combining liver stiffness measurement (LSM) with spleen stiffness measurement (SSM) significantly improves risk stratification in patients with PBC. In a study the addition of spleen stiffness to liver stiffness enhanced the prediction of liver decompensation, providing a more precise evaluation of portal hypertension. Furthermore, when combined with platelet count, this approach effectively identified patients with a low probability of harboring HRVs. This could allow clinicians to safely avoid unnecessary endoscopic procedures in selected patients, improving patient comfort and reducing healthcare costs. Therefore, our patients participating in this trial will undergo follow up (every 6 months) as per Standard of care. This includes a blood draw, FibroScan and Ultrasound. Together with this, 2 questionnaires will be completed (not as per SOC) and during the FibroScan, a spleen stiffness measurement will be performed.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
125

participants targeted

Target at P50-P75 for not_applicable

Timeline
18mo left

Started Jul 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 5, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 6, 2026

Completed
6 months until next milestone

Study Start

First participant enrolled

July 1, 2026

Expected
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2028

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2028

Last Updated

May 1, 2026

Status Verified

April 1, 2026

Enrollment Period

1.5 years

First QC Date

December 5, 2025

Last Update Submit

April 30, 2026

Conditions

Keywords

spleen stiffnessprimary biliairy cholangitis

Outcome Measures

Primary Outcomes (5)

  • Correlation between spleen stiffness measurement and biochemical assessment of severity of PBC.

    from signing the ICF till end of study (could be up to 5 years, assessments are done every 6 months)

  • Correlation between spleen stiffness measurement and clinical signs of portal hypertension, liver related events and PH-related bleeding

    from signing the ICF till end of study (could be up to 5 years, assessments are done every 6 months)

  • Correlation between spleen stiffness measurement and endoscopic signs of portal hypertension, liver related events and PH-related bleeding

    from signing the ICF till end of study (could be up to 5 years, assessments are done every 6 months)

  • Correlation between spleen stiffness measurement and quality of life assessment of severity of PBC.

    from signing the ICF till end of study (could be up to 5 years, assessments are done every 6 months)

  • Evaluation of the evolution of liver or spleen stiffness on treatment of PBC

    liver or spleen stiffness measurement is done using FibroScan

    from signing the ICF till end of study (could be up to 5 years, assessments are done every 6 months)

Study Arms (1)

Spleen stiffness measurement

EXPERIMENTAL
Procedure: Spleen stiffness measurement

Interventions

spleen stiffness measurement - during FibroScan

Spleen stiffness measurement

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ≥18y
  • Out-patient, followed at the UZ Brussels
  • Diagnosis of PBC based on cholestasis, AMA positivity and/or biopsy.
  • Under treatment with ursodeoxycholic acid and/or bezafibrate

You may not qualify if:

  • \<18y
  • Contra-indication for transient elastography (Fibroscan®) such as ascites or overt heart failure.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UZ Brussel

Brussels, 1090, Belgium

Location

MeSH Terms

Conditions

Liver Cirrhosis, Biliary

Condition Hierarchy (Ancestors)

Cholestasis, IntrahepaticCholestasisBile Duct DiseasesBiliary Tract DiseasesDigestive System DiseasesLiver DiseasesLiver CirrhosisFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 5, 2025

First Posted

January 6, 2026

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

January 1, 2028

Last Updated

May 1, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations